Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anything that is a material event has to be reported within three business days no hiding in the shadows allowed. Perhaps they had a meeting with Nasdaq which is allowed to present an argument for another extension if so, they are required to PR this to. Perhaps someone can explain what is going on here about this because I am scratching my head...
Again I say....
Request a meeting with the SEC and provide the rational for another extension this can be done before 180 day extension expires.
The shareholders own this company so this process would be the best option. IMO
In the event the company does not regain compliance with the Rule by X date NASDAQ will notify the company that its common stock will be delisted from the NASDAQ Capital Market, unless the company requests a hearing before a NASDAQ Hearings Panel. This information is being provided solely to comply with NASDAQ Listing Rules requiring public announcement of the company’s receipt of the letter from NASDAQ.
Request a meeting with the SEC and provide the rational for another extension this can be done before 180 day extension expires.
The shareholders own this company so this process would be the best option. IMO
In the event the company does not regain compliance with the Rule by X date NASDAQ will notify the company that its common stock will be delisted from the NASDAQ Capital Market, unless the company requests a hearing before a NASDAQ Hearings Panel. This information is being provided solely to comply with NASDAQ Listing Rules requiring public announcement of the company’s receipt of the letter from NASDAQ.
Did I miss something here? With the spin offs and recapitalization IMNP improved but their still under minimum bid price. Can any body shed some light on RS status?
To be compliant for NASDAQ I would say it is inevitable.
Previously NASDAQ Granted Extension To Immune Pharmaceuticals Inc. To Regain Compliance With Requirements Under NASDAQ Listing Rule 5810(c)(3)
Barring any substantial partnerships or news expect anywhere from
1/2 to 1/25 reverse split sometime in late December.
Jul 6 16
On July 6, 2016, Immune Pharmaceuticals Inc. received a notification from the Listing Qualifications Department of The NASDAQ Stock Market LLC (NASDAQ) indicating that the company had been granted an additional 180 calendar day extension, or until January 3, 2017, to regain compliance with the requirements under NASDAQ Listing Rule 5810(c)(3). The notification stated that Extension determination was based on the company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market, with the exception of the bid price requirement. The notification has no immediate effect on the NASDAQ listing or trading of the company’s common stock. As previously reported on a Current Report on Form 8-K dated January 11, 2016, the company had received a prior notification from NASDAQ, dated January 5, 2016, indicating that the company was not in compliance with the Rule because the minimum bid price of the company’s common stock on the NASDAQ Capital Market had closed below $1.00 per share for 30 consecutive business days. In the event the company does not regain compliance with the Rule by January 3, 2017, NASDAQ will notify the company that its common stock will be delisted from the NASDAQ Capital Market, unless the company requests a hearing before a NASDAQ Hearings Panel. This information is being provided solely to comply with NASDAQ Listing Rules requiring public announcement of the company’s receipt of the letter from NASDAQ.
The Clay play pump & cover at it again.
JJ I would agree it would be more helpful.EOM
I understand EOM
JJ I think he was being sarcastic an expression of disappointment in some cases. EOM
Well their is no update on the website about this supposed new role.
I will say this Avid Website has been very professionally redesigned while Peregrine Website is still very static.
Stephen T. Worsley
Vice President, Business Development
Stephen Worsley was appointed vice president of business development in November 2013 bringing with him over 25 years in the biotechnology industry with 16 of those in business development. Prior to joining Peregrine he was chief business officer at Centrose Pharmaceuticals and prior to that he held the position of vice president of business development at Intrexon Inc., Zosano Pharma Inc., (a spin out of Johnson & Johnson) and Raven Biotechnologies, Inc. (acquired by MacroGenics). In addition, he was director of business development at Abgenix (acquired by Amgen), Tripos Drug Discovery, and OHM Technologies (acquired by Carlyle Group). Stephen holds an MBA in finance from the University of Washington and a Bachelor of Science in international economics and finance from the University of Utah.
SK needs to belly up to the table it is time to make a deal or should I say long overdue.
Compliance, pipeline and non dilution are positive factors though?
Hopefully we are on the menu at some point?
He is trying to be a wrecking ball for the Halo Rally?
*Adam Feuerstein Tweets: $HALO followers, did you read the PR closely? Seems like they're only reporting positive results from a subset of pancreatic cancer pats.
I guess his leaving was not material enough to PR to shareholders.
Dr Hutchins schedule
Jan17-20: Phacilitate's Immunotherapy World Conf., Miami http://www.immunotherapyforum.com
...Jan18 12:25-12:40pm: Dr. Jeff Hutchins (VP/PreClinRes), “Combination Immunotherapies - Opening the Gate: Increasing Tumor Infiltrating Activated T-Cells to Optimize & Expand the Benefits of Immune Checkpoint Therapies”
Apr10-12: Immune Profiling World Congress 2017, WashDC (part of “World Vaccine Congress 2017”) http://tinyurl.com/zlr5cyj
...4-11-17 12:10pm: Dr. Jeff Hutchins(VP/PreClinRes.), “Increasing the Benefits of Immune Checkpoint Therapies Thru Increased Tumor Infiltrating Activated T-Cells”
June12-17: CHI’s 2nd Annual Immunotherapy & Combinations Conf., Boston http://www.worldpreclinicalcongress.com/Cancer-Immunotherapy-Combinations
...Dr. Jeff Hutchins(VP/PreClinRes.): “Expansion & Activation of T-Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”
I do not see Dr. Hutchins on the Peregrine website anymore.
Perhaps he has been off for some time and haven't noticed.
I think I am conflating him with Dr. Robert Garnick. Wrong DR.
Thanks for pointing this out but I still think he is in very good shape on the money front.
Well they would be wrong EOM.
Dr. Hutchins maneuvered Peregrine into several collaborations and the program is developing in their I/O space with Bavi. Interesting I see Bavi as being very synergistic with the HTBX pipeline. I own them both so should become interesting
Well let's see the science is solid he becomes CSO, decent salary of 305K and an option to purchase 200,000 shares of the Company’s common stock. He is already loaded with money so I think CSO is very appealing to him the rest is icing on the cake. Being CSO could parley into other potential avenues for Bavi.
Chey I heard some chatter and it became legitimate this time.
Wook,
Heard some talk of this possibility since I own HTBX. See what happens next. Bavi could help here for sure.
Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer
8:00 am ET January 4, 2017 (Globe Newswire) Print
-- Industry veteran, Dr. Hutchins, to advance Heat's platform technologies and pursue immunotherapy combinations
-- Former CSO Taylor Schreiber, M.D., Ph.D., to chair Heat's Scientific Advisory Board and advance Shattuck Labs, Inc., a new biotechnology company focused on developing technology exclusively licensed from Heat
Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient's immune system against cancer, announced the appointment of Jeff Hutchins, Ph.D., as Chief Scientific Officer and Senior Vice President of Preclinical Development. Dr. Hutchins will be overseeing Heat's research efforts, bringing over 24 years of research and clinical development experience from both large pharmaceutical and biotechnology companies.
Most recently, Dr. Hutchins served as Vice President of Preclinical Research for Peregrine Pharmaceuticals, Inc., a biopharmaceutical company developing therapeutics to fight cancer and infectious diseases. Dr. Hutchins was responsible for building out the research program for Peregrine's lead product candidate, bavituximab, a chimeric monoclonal antibody designed to target phosphatidylserine. Currently in clinical development, bavituximab is being evaluated in combination through Peregrine-funded trials and strategic collaborations, including AstraZeneca and the National Comprehensive Cancer Network (NCCN).
"I would like to welcome Dr. Hutchins to the Heat team," commented Jeff Wolf, Heat's Chief Executive Officer. "He brings a tremendous amount of industry experience, including preclinical research, clinical development and manufacturing. His expertise aligns with Heat's current pipeline and priorities, and positions us strongly as we move into 2017."
"This is a bittersweet announcement for Heat, as Dr. Schreiber has been with Heat since inception and has played an instrumental role in advancing our ImPACT and ComPACT platform technologies," added Mr. Wolf. "Taylor will be joining Shattuck Labs, a biotechnology company focused on agonist redirected checkpoint therapeutics for cancer immunotherapy, as their CSO. Shattuck Labs is independently funded by outside investors and Heat has the potential to benefit from the success of Shattuck through milestone and royalty payments as they advance their product candidates. We look forward to continuing to work with Taylor in his newly appointed role as Chairman of our Scientific Advisory Board."
"I am excited to be joining Jeff and his team at Heat, and to be continuing my pursuit in immuno-oncology and infectious diseases," stated Dr. Hutchins. "I understand both the challenges and rewards of working within a start-up biotechnology environment, and am looking forward to offering my expertise in continuing to advance product candidates into the clinic and hopefully into the marketplace."
Prior to joining Peregrine in 2012, Dr. Hutchins served as Vice President, Preclinical Development at Inhibitex Inc, which was acquired by Bristol-Myers Squibb. From 1991 to 2000, Dr. Hutchins held several senior scientist positions in Discovery Research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College. Dr. Hutchins earned a B.S. in Biology from Oral Roberts University, a Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at the M.D. Anderson Cancer Center and conducted postdoctoral training in the University of Southern California's Department of Microbiology at the Norris Cancer Center. Dr. Hutchins' publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient's immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat's highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells (one of the human immune system's most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients' immune response. Currently, Heat is conducting a Phase 1b trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).
Heat's wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat's gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami. The Zolovax patent portfolio also includes gp96 vaccines targeting West Nile virus, Dengue and yellow fever among others
Would like to see this thing start to gain some real traction.
Need that "investor fever" of times gone by only this time the ball drops on the favorable side for the investors here for sustained growth and not just a shot lived spike for the traders.
Check SEC Filings you will see extension granted.
BIO 100% correct on assessment.
Happy New Year to all LONGS & Traders
Been doing that for months yet still leave a large amount in just in case THE PR comes that no one is expecting.
Interesting times ahead for LONGS IMO
With the cash burn going down steadily on trails combined with Avid revenue projections in subsequent QTRS ahead, I would expect the numbers below to translate more positive. The PPS will improve to reflect the more positive numbers.
The more speculative factor of PPS movement will be on the anticipation of the potential prospects of partnering as bio-markers and results of combo trials through MSK and NCNN mature.
Currently:
The stock has Return on Assets (ROA) of -43.9 percent. Return on Equity (ROE) stands at -101% and Return on Investment (ROI) of -112.5 percent.
The stock is currently showing YTD performance of -73.03 Percent. The company has Beta Value of 1.19 and ATR value of 0.02. The Weekly and Monthly Volatility stands at 8.90% and 7.49%.
Maybe will get another PR update on some more Bio-markers from the data mining process out of Sunrise near term.
Well might as well buy more at these prices. Done.
Yes been doing thew same for some time.
So far as I know unless someone else has better information:
In the event the company does not regain compliance with the Rule by January 3, 2017, NASDAQ will notify the company that its common stock will be delisted from the NASDAQ Capital Market, unless the company requests a hearing before a NASDAQ Hearings Panel. This information is being provided solely to comply with NASDAQ Listing Rules requiring public announcement of the company’s receipt of the letter from NASDAQ.
You would be correct it is coming hold on to your shares. IMO
HD thanks for the influx of information in short, one RS under PPHM in 2009 and one under TCLN in 1987. Understood, investors cringed as a result. Will another one occur? It seems most likely but....?
Thanks for refreshing memory
I go back to the TCLN days. HD counts two RS so far, well one was way back in the TCLN days in 1986 I believe.
It is called the pump then the Clay short crew mop up.
well you got you answer
(4)The authorization of the filing of an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a specific ratio, within a range of 1-for-2 and 1-for-25, to be determined by the Company’s Board of Directors in its sole discretion and effected, if at all, on or before December 15, 2017 was approved, based on the following votes:
Votes For 62,751,519
Votes Against 13,102,528
Votes Abstain 2,643,750
Broker non-vote 0